-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Clinical Trial Design
-
Timing is of the Essence: Commentary on NRG/Alliance LU005 Results
While the trial did not yield a survival benefit, Dr. Adam Schoenfeld says the study strengthens the case that immunotherapy timing and sequencing matter.
-
Phase II Trial Evaluates Amivantamab Plus Lazertinib in EGFR-Mutant Lung Cancers With New or Progressing Brain Metastases or Leptomeningeal Disease
In addition to encouraging intracranial activity and survival outcomes, Dr. Mark Jeng details how the findings highlight the limitations of current LMD assessment tools and demonstrate the feasibility of conducting prospective trials within this population.
-
What Do Recent ODAC Decisions Mean for Lung Cancer Drug Development and Clinical Trial Design?
In a Q&A with ILCN, Dr. John V. Heymach addresses several rulings from the Oncologic Drugs Advisory Committee and important lessons for research teams.
-
IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation Strategies
Although clinical trials are vitally important to researchers working to improve therapies for lung cancer, clinical trials also provide what could be lifesaving treatments to those patients on trials. When there is a disruption to the clinical trial pipeline—anything from funding to barriers to in-person site visits for treatments and follow up exams— lung cancer…
-
Cancer Clinical Trial Compensation: Undue or Long Overdue?
When compensating participants in clinical trials, the objective is to show appreciation and consideration for a patient’s time and expenses without exerting undue influence. The Office for Human Research Protections of the U.S. Department of Health and Human Services (HHS) defines undue influence as a potential consequence of an “offer of an excessive or inappropriate…
-
Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials
By now, investigators, sponsors, clinicians, and patients are widely aware of the crisis facing cancer clinical trials. With scientific discoveries occurring more rapidly than ever, there is a growing need to bring novel therapies to patients as efficiently as possible. Yet, in the United States, fewer than 3% of adults with cancer enroll in clinical…